VCYT insider filings
VERACYTE, INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-29. Screen VCYT transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 13 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 13 legs across 9 filings by 7 insiders — 62,609 shares, $2,858,989 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
- Largest priced transaction: sale of 14,850 shares @ $50.00 ($742,573) by EASTHAM KARIN, filed 2026-10-28.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Holstein Jens — Director | 2 | — | 3 legs · 20,000 sh · $932,247 | 4 |
| EASTHAM KARIN — Director | 1 | — | 1 leg · 14,850 sh · $742,573 | 2 |
| Febbo Phillip G. — Chief Scientific & Med Officer | 1 | — | 2 legs · 13,110 sh · $564,410 | 1 |
| Bhanji Muna — Director | 2 | — | 2 legs · 3,728 sh · $161,553 | — |
| Leite John — Global Chief Commercial Off | 2 | — | 1 leg · 4,015 sh · $160,600 | 1 |
| Chambers Rebecca — Chief Financial Officer | 1 | — | 2 legs · 3,652 sh · $157,394 | 1 |
| McGuire Annie — EVP, General Counsel | 1 | — | 2 legs · 3,254 sh · $140,212 | 1 |
| Wygant Jonathan — VP, Chief Accounting Officer | 2 | — | — | 2 |
| Stapley Marc — Chief Executive Officer, Director | 1 | — | — | 1 |
Recent insider filings — VERACYTE, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-29 | 4 | Wygant Jonathan — VP, Chief Accounting Officer | Tax withholding (F): 1,306 @ $50.31 | EDGAR |
| 2026-10-28 | 4 | EASTHAM KARIN — Director | Option exercise (M): 10,000 @ $27.01 · Sale (S): 14,850 @ $50.00 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-10-28 | 4 | Holstein Jens — Director | Option exercise (M): 7,500 @ $35.30 · Sale (S): 7,500 @ $47 · Option exercise (M): 7,500 @ $35.30 · Sale (S): 7,500 @ $50 · Option exercise (M): 7,500 (derivative) @ $0 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-10-20 | 4 | Bhanji Muna — Director | Sale (S): 1,864 @ $43.70 | EDGAR |
| 2026-09-22 | 4 | Leite John — Global Chief Commercial Off | Sale (S): 4,015 @ $40 | EDGAR |
| 2026-09-16 | 4 | Holstein Jens — Director | Sale (S): 5,000 @ $40.95 | EDGAR |
| 2026-09-04 | 4 | Stapley Marc — Chief Executive Officer, Director | Tax withholding (F): 8,782 @ $44.88 | EDGAR |
| 2026-09-04 | 4 | McGuire Annie — EVP, General Counsel | Tax withholding (F): 3,215 @ $44.88 · Sale (S): 2,154 @ $42.79 · Sale (S): 1,100 @ $43.67 | EDGAR |
| 2026-09-04 | 4 | Chambers Rebecca — Chief Financial Officer | Tax withholding (F): 3,603 @ $44.88 · Sale (S): 2,477 @ $42.81 · Sale (S): 1,175 @ $43.71 | EDGAR |
| 2026-09-04 | 4 | Febbo Phillip G. — Chief Scientific & Med Officer | Tax withholding (F): 3,639 @ $44.88 · Sale (S): 10,405 @ $42.89 · Sale (S): 2,705 @ $43.66 | EDGAR |
| 2026-09-04 | 4 | Leite John — Global Chief Commercial Off | Tax withholding (F): 3,961 @ $44.88 | EDGAR |
| 2026-09-04 | 4 | Wygant Jonathan — VP, Chief Accounting Officer | Tax withholding (F): 1,361 @ $44.88 | EDGAR |
| 2026-09-03 | 4 | Bhanji Muna — Director | Sale (S): 1,864 @ $42.97 | EDGAR |
| 2026-06-22 | 4 | EASTHAM KARIN — Director | Sale (S): 3,200 @ $52.78 · Sale (S): 529 @ $53.55 | EDGAR |
| 2026-06-15 | 4 | Miller Thomas F. — Director | Grant/award (A): 5,272 @ $0 | EDGAR |
| 2026-06-15 | 4 | Barr Eliav — Director | Grant/award (A): 5,272 @ $0 | EDGAR |
| 2026-06-15 | 4 | Bhanji Muna — Director | Grant/award (A): 5,272 @ $0 | EDGAR |
| 2026-06-15 | 4 | Holstein Jens — Director | Grant/award (A): 5,272 @ $0 | EDGAR |
| 2026-06-15 | 4 | Shafer David Brent — Director | Grant/award (A): 5,272 @ $0 | EDGAR |
| 2026-06-15 | 4 | EPSTEIN ROBERT S — Director | Grant/award (A): 5,272 @ $0 | EDGAR |
| 2026-06-15 | 4 | EASTHAM KARIN — Director | Grant/award (A): 5,272 @ $0 | EDGAR |
| 2026-06-15 | 4 | JONES EVAN/ FA — Director | Grant/award (A): 5,272 @ $0 | EDGAR |
| 2026-06-04 | 4 | Leite John — Global Chief Commercial Off | Tax withholding (F): 4,059 @ $47.80 · Sale (S): 13,975 @ $50.07 | EDGAR |
| 2026-06-04 | 4 | McGuire Annie — EVP, General Counsel | Tax withholding (F): 3,292 @ $47.80 · Sale (S): 1,400 @ $49.31 · Sale (S): 1,776 @ $50.12 | EDGAR |
| 2026-06-04 | 4 | Chambers Rebecca — Chief Financial Officer | Tax withholding (F): 3,693 @ $47.80 · Sale (S): 1,600 @ $49.28 · Sale (S): 1,961 @ $50.09 | EDGAR |
| 2026-06-04 | 4 | Febbo Phillip G. — Chief Scientific & Med Officer | Tax withholding (F): 3,730 @ $47.80 | EDGAR |
| 2026-06-04 | 4 | Wygant Jonathan — VP, Chief Accounting Officer | Tax withholding (F): 1,361 @ $47.80 | EDGAR |
| 2026-06-04 | 4 | Stapley Marc — Chief Executive Officer, Director | Tax withholding (F): 9,012 @ $47.80 · Option exercise (M): 138,051 @ $36.60 · Sale (S): 138,051 @ $50.12 · Option exercise (M): 138,051 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Wygant Jonathan — VP, Chief Accounting Officer | Option exercise (M): 24,000 @ $24.80 · Sale (S): 24,000 @ $45.40 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | EPSTEIN ROBERT S — Director | Sale (S): 10,000 @ $44.01 | EDGAR |
| 2026-05-08 | 4 | McGuire Annie — SVP, General Counsel | Sale (S): 5,102 @ $38.05 · Sale (S): 5,102 @ $40 | EDGAR |
| 2026-04-14 | 4 | Haas Kevin Richard — Chief Dev and Tech Officer | Grant/award (A): 44,221 @ $0 | EDGAR |
| 2026-03-10 | 4 | Leite John — Chief Commercial Officer-CLIA | Grant/award (A): 36,181 @ $0 · Grant/award (A): 6,578 @ $0 | EDGAR |
| 2026-03-10 | 4 | McGuire Annie — SVP, General Counsel | Grant/award (A): 32,892 @ $0 · Grant/award (A): 26,314 @ $0 | EDGAR |
| 2026-03-10 | 4 | Chambers Rebecca — Chief Financial Officer | Grant/award (A): 36,181 @ $0 · Grant/award (A): 13,157 @ $0 | EDGAR |
| 2026-03-10 | 4 | Febbo Phillip G. — Chief Scientific & Med Officer | Grant/award (A): 29,603 @ $0 · Grant/award (A): 6,578 @ $0 | EDGAR |
| 2026-03-10 | 4 | Wygant Jonathan — VP, Chief Accounting Officer | Grant/award (A): 10,525 @ $0 | EDGAR |
| 2026-03-10 | 4 | Stapley Marc — Chief Executive Officer, Director | Grant/award (A): 92,099 @ $0 | EDGAR |
| 2026-03-06 | 4 | Leite John — Chief Commercial Officer-CLIA | Sale (S): 5,260 @ $35.19 | EDGAR |
| 2026-03-06 | 4 | McGuire Annie — SVP, General Counsel | Sale (S): 4,994 @ $35.29 · Sale (S): 1,664 @ $36.34 | EDGAR |
| 2026-03-06 | 4 | Chambers Rebecca — Chief Financial Officer | Sale (S): 4,400 @ $35.55 · Sale (S): 13,941 @ $36.33 | EDGAR |
| 2026-03-06 | 4 | Stapley Marc — Chief Executive Officer, Director | Sale (S): 19,244 @ $35.56 · Sale (S): 26,279 @ $36.28 | EDGAR |
| 2026-03-04 | 4 | Leite John — Chief Commercial Officer-CLIA | Tax withholding (F): 7,517 @ $36.01 | EDGAR |
| 2026-03-04 | 4 | McGuire Annie — SVP, General Counsel | Tax withholding (F): 6,902 @ $36.01 | EDGAR |
| 2026-03-04 | 4 | Chambers Rebecca — Chief Financial Officer | Tax withholding (F): 7,234 @ $36.01 | EDGAR |
| 2026-03-04 | 4 | Febbo Phillip G. — Chief Scientific & Med Officer | Tax withholding (F): 6,035 @ $36.01 · Sale (S): 13,425 @ $36.16 | EDGAR |
| 2026-03-04 | 4 | Wygant Jonathan — VP, Chief Accounting Officer | Tax withholding (F): 3,006 @ $36.01 | EDGAR |
| 2026-03-04 | 4 | Stapley Marc — Chief Executive Officer, Director | Tax withholding (F): 19,455 @ $36.01 | EDGAR |
| 2026-03-02 | 4 | Febbo Phillip G. — Chief Scientific & Med Officer | Grant/award (A): 71,806 @ $0 · Tax withholding (F): 24,486 @ $38.75 | EDGAR |
| 2026-03-02 | 4 | Stapley Marc — Chief Executive Officer, Director | Grant/award (A): 139,074 @ $0 · Tax withholding (F): 35,841 @ $38.75 | EDGAR |
Recent 8-K events — VERACYTE, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VCYT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs